COMMUNIQUÉS West-GlobeNewswire

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational [...]
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
13/07/2026
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well- [...]
First patient treated in Phase 2 A-TANGO trial for acute-on-chronic liver failure
13/07/2026
Randomized phase 2 study evaluating Yaqrit’s toll-like receptor 4 (TLR4) antagonist YAQ005 alone and in combination with G-CSF for acute-on-chronic liver failure (ACLF) Investigational combination G-TAK is designed to [...]
FDA Grants De Novo Classification to Claria Medical for Device Designed to Improve Safety and Efficiency of Hysterectomy Procedures
13/07/2026
Claria System is the first integrated tissue containment and removal system authorized by the FDA, granted through its Safer Technologies Program for its potential impact on women’s health MOUNTAIN VIEW, Calif., July 13 [...]
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative [...]
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026
IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation THE [...]
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
13/07/2026
FDA grant of RMAT designation to Allocetra™ reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face declined quality-of- [...]
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
13/07/2026
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent [...]
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
13/07/2026
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim [...]
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
13/07/2026
Topline data expected to be available late 3Q2027 SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on [...]
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that it has acquired Buddy Healthcare Ltd Oy (“Buddy Healthcare”), a care coordination [...]
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
13/07/2026
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
13/07/2026
- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development - [...]
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]
Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference
13/07/2026
SAN FRANCISCO, July 13, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in Canaccord Genuity’s 46th [...]
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and [...]
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
13/07/2026
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]

Pages